Literature DB >> 15476462

Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years.

T Sarasoja1, J Wikström, J Paltamaa, M Hakama, M-L Sumelahti.   

Abstract

OBJECTIVE: We estimated the prevalence and incidence of multiple sclerosis (MS) in central Finland up to 2000. Rates were compared with those in other areas in Finland. MATERIAL AND
METHOD: MS cases were identified in the hospital registry by ICD codes for demyelinating diseases from 1979 to 2000. Cases with definite MS were included. Incidence and prevalence were calculated with 95% CI and standardization was performed using direct method.
RESULTS: In 1993 prevalence was 59/10(5) (n = 153). Incidence in 1979-93 was 3.8/10(5) person-years (n = 126). Rates are similar to average in areas with known rates of MS in Finland but substantially less than the over twofold MS risk in the neighbouring district Seinajoki. Extended follow-up to 2000 in central Finland showed increasing prevalence up to 105/10(5) (n = 277) and a significant increase in incidence 1994-98 up to 9.2/10(5) (n = 105). At the same time the diagnostic use of MRI increased up to 97%.
CONCLUSION: Central Finland represents an average risk area of MS when compared with other areas of Finland but still a high risk in global comparison. The recent rapid increase in both prevalence and incidence is largely accounted for by increased use of MRI. Copyright Blackwell Munksgaard, 2004.

Entities:  

Mesh:

Year:  2004        PMID: 15476462     DOI: 10.1111/j.1600-0404.2004.00326.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  12 in total

1.  Are the prevalence and incidence of multiple sclerosis changing?

Authors:  Julián Benito-León
Journal:  Neuroepidemiology       Date:  2011-04-20       Impact factor: 3.282

Review 2.  Environmental factors and their timing in adult-onset multiple sclerosis.

Authors:  Adam E Handel; Gavin Giovannoni; George C Ebers; Sreeram V Ramagopalan
Journal:  Nat Rev Neurol       Date:  2010-02-16       Impact factor: 42.937

3.  Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.

Authors:  A Alonso; S S Jick; M J Olek; M A Hernán
Journal:  J Neurol       Date:  2007-10-01       Impact factor: 4.849

4.  Ten-year follow-up of health-related quality of life among ambulatory persons with multiple sclerosis at baseline.

Authors:  Aki Rintala; Arja Häkkinen; Jaana Paltamaa
Journal:  Qual Life Res       Date:  2016-06-30       Impact factor: 4.147

Review 5.  Temporal trends in the incidence of multiple sclerosis: a systematic review.

Authors:  Alvaro Alonso; Miguel A Hernán
Journal:  Neurology       Date:  2008-07-08       Impact factor: 9.910

Review 6.  Epidemiology and treatment of multiple sclerosis in elderly populations.

Authors:  Caila B Vaughn; Dejan Jakimovski; Katelyn S Kavak; Murali Ramanathan; Ralph H B Benedict; Robert Zivadinov; Bianca Weinstock-Guttman
Journal:  Nat Rev Neurol       Date:  2019-06       Impact factor: 42.937

7.  Geomagnetic disturbances may be environmental risk factor for multiple sclerosis: an ecological study of 111 locations in 24 countries.

Authors:  Seyed Aidin Sajedi; Fahimeh Abdollahi
Journal:  BMC Neurol       Date:  2012-09-24       Impact factor: 2.474

Review 8.  Incidence and prevalence of multiple sclerosis in Europe: a systematic review.

Authors:  Elaine Kingwell; James J Marriott; Nathalie Jetté; Tamara Pringsheim; Naila Makhani; Sarah A Morrow; John D Fisk; Charity Evans; Sarah Gabrielle Béland; Sophie Kulaga; Jonathan Dykeman; Christina Wolfson; Marcus W Koch; Ruth Ann Marrie
Journal:  BMC Neurol       Date:  2013-09-26       Impact factor: 2.474

9.  The causal cascade to multiple sclerosis: a model for MS pathogenesis.

Authors:  Douglas S Goodin
Journal:  PLoS One       Date:  2009-02-26       Impact factor: 3.240

10.  The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities.

Authors:  Douglas S Goodin
Journal:  BMC Neurol       Date:  2016-04-27       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.